Published in Proc Natl Acad Sci U S A on September 05, 2003
15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med (2004) 1.84
A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem Cell Biol (2004) 1.62
Randomised aspirin assignment and risk of adult-onset asthma in the Women's Health Study. Thorax (2008) 1.45
Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol (2010) 1.34
Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol (2005) 1.17
Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol (2004) 1.10
NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol (2012) 1.03
Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol (2007) 0.86
Building a better aspirin: gaseous solutions to a century-old problem. Br J Pharmacol (2007) 0.85
Aspirin and decreased adult-onset asthma: randomized comparisons from the physicians' health study. Am J Respir Crit Care Med (2006) 0.84
Resolution of inflammation in periodontitis. J Periodontol (2005) 0.83
Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia. J Cancer Prev (2013) 0.82
Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells. Clin Cancer Res (2009) 0.80
Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endothelium. Am J Physiol Cell Physiol (2011) 0.79
Organic nitrate metabolism and action: toward a unifying hypothesis and the future-a dedication to Professor Leslie Z. Benet. J Pharm Sci (2013) 0.78
Wnt/β-Catenin Signaling Pathway in Skin Carcinogenesis and Therapy. Biomed Res Int (2015) 0.77
NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology (2005) 0.77
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. Br J Clin Pharmacol (2010) 0.75
Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets β-catenin. Drug Des Devel Ther (2013) 0.75
The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs. Clin Rheumatol (2005) 0.75
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem (2000) 8.86
The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med (2001) 5.29
Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A (1991) 5.07
Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A (1995) 3.72
Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology (2003) 3.21
Aspirin as an antiplatelet drug. N Engl J Med (1994) 2.72
Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest (1990) 2.66
The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol (1995) 2.56
NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology (2000) 2.43
Why there are two cyclooxygenase isozymes. J Clin Invest (2001) 2.13
Concern NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation (2002) 2.09
Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology (2000) 1.97
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther (1994) 1.79
Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. J Pharmacol Exp Ther (1998) 1.66
Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest (1995) 1.55
Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest (2001) 1.49
Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov (2002) 1.33
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology (1999) 1.24
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J (2003) 1.09
Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab Dispos (2000) 1.06
Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol (2003) 0.94
Urinary excretion of lipoxin A(4) and related compounds: development of new extraction techniques for lipoxins. Lab Invest (2002) 0.94
Determination of acetylsalicylic acid and salicylic acid in skin and plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1998) 0.86
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med (2005) 4.79
Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood (2002) 3.58
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology (2003) 3.21
Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology (2006) 2.98
Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci (2004) 2.64
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology (2005) 2.58
Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys (2008) 2.30
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology (2008) 2.28
Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol (2002) 2.16
Concern A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A (2004) 2.13
Concern NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation (2002) 2.09
The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology (2006) 2.08
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology (2004) 1.96
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 1.85
Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A (2004) 1.76
Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem (2010) 1.63
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther (2005) 1.56
Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J Am Coll Cardiol (2004) 1.52
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology (2009) 1.49
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 1.47
A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci U S A (2005) 1.45
PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology (2004) 1.42
Galectin-1 suppresses experimental colitis in mice. Gastroenterology (2003) 1.41
Pseudo-pseudo-obstruction. Eur J Gastroenterol Hepatol (2004) 1.40
Pentraxin 3 and Platelet Activation in Obese Patients After Gastric Banding. Circ J (2015) 1.39
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology (2005) 1.38
NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci U S A (2002) 1.36
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proc Natl Acad Sci U S A (2003) 1.32
A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther (2005) 1.30
NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun (2004) 1.28
Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity (2002) 1.25
Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med (2007) 1.23
CD1-restricted recognition of exogenous and self-lipid antigens by duodenal gammadelta+ T lymphocytes. J Immunol (2007) 1.20
Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. Can J Physiol Pharmacol (2003) 1.17
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther (2005) 1.16
Long-term study on the effects of visual biofeedback and muscle training as a therapeutic modality in pelvic floor dyssynergia and slow-transit constipation. Dis Colon Rectum (2004) 1.15
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
Pasta naturally enriched with isoflavone aglycons from soy germ reduces serum lipids and improves markers of cardiovascular risk. J Nutr (2007) 1.15
Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. Gastroenterology (2008) 1.14
Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci U S A (2002) 1.13
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther (2005) 1.11
NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol (2004) 1.10
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology (2011) 1.10
G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation (2004) 1.09
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J (2003) 1.09
The enteric nervous system in chagasic and idiopathic megacolon. Am J Surg Pathol (2007) 1.07
Increased circulating Interleukin-18 levels in centenarians with no signs of vascular disease: another paradox of longevity? Exp Gerontol (2003) 1.07
Gastrointestinal inflammation: a central component of mucosal defense and repair. Exp Biol Med (Maywood) (2006) 1.06
Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract. Dig Liver Dis (2009) 1.06
Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol (2008) 1.03
Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients. J Med Virol (2003) 1.02
Toward a definition of colonic inertia. World J Gastroenterol (2004) 1.02
A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci U S A (2010) 1.01
Retracted A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. Br J Pharmacol (2002) 1.01
5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther (2006) 1.00
Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity. FASEB J (2011) 1.00
Proteinase-activated receptor (PAR)-1 and -2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2. J Pharmacol Exp Ther (2002) 0.99
Sildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow. Br J Pharmacol (2005) 0.98
Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One (2012) 0.98
Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J Neurochem (2004) 0.98
Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus. Hum Pathol (2008) 0.98
Normal aspects of colorectal motility and abnormalities in slow transit constipation. World J Gastroenterol (2005) 0.98
Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion (2002) 0.98
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol (2009) 0.98
Hydrogen sulfide: a rescue molecule for mucosal defence and repair. Dig Dis Sci (2012) 0.97
The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. Hepatology (2008) 0.96
Letter by Wallace and Chan regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin". Circulation (2013) 0.96
Alterations in colonic motility and relationship to pain in colonic diverticulosis. Clin Gastroenterol Hepatol (2005) 0.96
Colonic propulsive impairment in intractable slow-transit constipation. Arch Surg (2003) 0.96
Eukaryotic and prokaryotic contributions to colonic hydrogen sulfide synthesis. Am J Physiol Gastrointest Liver Physiol (2011) 0.95
Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol (2003) 0.94
Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood) (2005) 0.94
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Can J Gastroenterol (2004) 0.94
Abnormal colonic propagated activity in patients with slow transit constipation and constipation-predominant irritable bowel syndrome. Digestion (2003) 0.94
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB J (2010) 0.93
Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc Natl Acad Sci U S A (2002) 0.93
Twenty-four-hour manometric study of colonic propulsive activity in patients with diarrhea due to inflammatory (ulcerative colitis) and non-inflammatory (irritable bowel syndrome) conditions. Int J Colorectal Dis (2004) 0.93
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One (2012) 0.93
Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. J Pharmacol Exp Ther (2004) 0.93